A double-blind study was set up to investigate the effect of pretreatment with lignocaine on the incidence of potassium chloride infusion pain. Twenty-eight patients were randomly allocated into two equal groups. Patients in both groups were hypokalaemic and were scheduled for replacement consisting of potassium chloride 20 mmol diluted to 100 ml in dextrose 5% solution administered over two hours. Group A (lignocaine) patients were pretreated with a bolus dose lignocaine 3 ml 1%, Group B (control) received isotonic saline 3 ml. The incidence of potassium chloride infusion pain was significantly reduced in Group A. There was no adverse effect reported. This study demonstrates the efficacy of bolus dose of lignocaine in alleviating injection pain for the duration of a two-hour continuous infusion.
Hypokalaemia is a common clinical problem. For the anaesthetist, the primary concern is the potential risk of cardiac arrhythmia. This concern has been fostered by the well-known effect of cations on the electrophysiology of excitable cells l and of hypokalaemia on the pacemakers of the heart. 2 Locally, a popular regimen for the rapid correction of severe hypokalaemia was to infuse potassium chloride 20 mmol diluted to 100 ml in dextrose 5% over a two-hour period. This was unfortunately a painful experience for many patients. The present study was designed to investigate the incidence of potassium chloride infusion pain and determine whether it can be significantly reduced by pretreatment with lignocaine.
MATERIALS AND METHODS Twenty-eight adult Chinese patients (aged 25-75 years) with hypokalaemia « 3.5 mmol/l) were studied. The study was approved by the Hospital Ethical Committee and all patients gave informed consent. Those with a history of epilepsy, cardiac arrhythmia and sensitivity to lignocaine were excluded from participating.
The patients were randomly assigned according to date of admission into one of two groups. All were scheduled to receive a standard correction regimen of potassium chloride 20 mmol diluted to 100 ml in dextrose 5% solution to be infused over a period of two hours through a 20-gauge Jelco cannula inserted over the dorsum of the hand. Prior to starting the infusion, a venous tourniquet was applied over the mid forearm. In the study group, lignocaine 3 ml I % was given as a bolus dose. After an interval of 30 seconds the tourniquet was released and the potassium chloride infusion commenced. A similar technique was used for the control group, but instead of lignocaine, isotonic saline 3 ml was injected.
Patients were asked whether the infusion they were receiving was painful. Pain was assessed at the end of each half-hour period for two hours on a four-point ordered categories scale (0 = no pain; 1 = mild pain; 2 = moderate pain; 3 = severe pain). Neither the patient nor the scorer (nursing staff in charge of the patient) knew which treatment group the patient was in. The bolus dose of either lignocaine 1 % or isotonic saline was given by the principal author who was not blinded to the solution given.
Mean arterial blood pressure (MAP), heart rate (HR) and ECG changes were recorded just before, at one minute and at five minutes after tourniquet release.
The two groups were compared using Mann-Whitney V-tests (pain experienced) and Student's t test (other data). P < 0.05 was considered to indicate statistical significance. The two groups were similar with regard to age, body weight, sex and severity of hypokalaemia (Table I) . When lignocaine I % was given as pretreatment prior to the infusion of potassium chloride infusion, it did not affect the mean arterial pressure or heart rate ( Table 2) . No other adverse effect was reported.
During the infusion of potassium chloride in the control group, the majority experienced pain ( Table 3) ; 79% (11114) reported moderate to severe pain at the start of infusion, 72% (10114) after one hour and 50% (7114) after two hours.
The use of lignocaine I % as pretreatment significantly reduced the incidence of pain (Table  4 ). No patient complained of pain at the start of the infusion, 14% (2114) reported moderate to severe pain after the first hour, and 22% (3114) after two hours.
DISCUSSION
Venous sequelae secondary to the intravenous administration of drugs is a common clinical problem. They range from the unpleasant problem of pain during injection to the more serious thrombophlebitis. 3 Pain on injection has been reported with many intravenous anaesthetic agents such as methohexitone,4 etomidate,5 propofol 6 and the sedative diazepam. It has been noted that the addition of vitamins, antibiotics and potassium interval  No pain Mild pain  pain  pain   Start  2  I  2  9  Ih hour  3  5  5  1 hour  3  5  5  Ilh hours  I  4  6  3  2 hours  2  5  5  2 Values are number of patients.
chloride to infusion fluids 7 is also associated with injection pain. Our study confirms the common clinical observation that the peripheral intravenous administration of potassium chloride solution is accompanied by a high incidence of pain. There are a number of possible causes of injection pain during the administration of intravenous drugs. It may be a result of direct chemical and osmotic irritation of the intima. This is particularly important with the propylene glycol formulation of etomidate, 8 the original preparation of propofol in 16% Cremophor EL9 and diazepam in organic solvent. ID Irritation can result from mechanical distention because of the large volume of the drug injected. It is also possible that the particularly sensitive intima comes into contact with a greater concentration of the drug during a rapid injection compared with a gradual one.
Prevention or reduction of pain has been attempted in several ways. Injection into large veins in the forearm or antecubital fossa is less painful than injection into the small dorsal veins of the hand.1O Dilution of drugs into rapidly running drips also helps. Reformulation in soy-bean oil almost completely prevents the pain of injection of diazepam 11 and etomidate. 12 The use of intravenous lignocaine immediately before injection of methohexitone 13 or propofol, the addition of lignocaine to etomidate 14 and propofol emulsion 15 have been shown to significantly reduce the frequency of injection pain.
Pretreatment with intravenous lignocaine in our study significantly reduced the pain of a two-hour potassium chloride infusion. To date, we are not aware of any study which demonstrates the efficacy of lignocaine in alleviating injection pain over a useful period of time. Previous studies have only shown that lignocaine has an immediate effect on injection pain. One patient in Group A (lignocaine) complained of severe pain at the half-hour period and this was most likely due to some degree of extravasation of the potassium solution.
Veins, like arteries, are richly supplied with nerves fibres. Apart from the post-ganglionic sympathetic efferents, there are also primary afferents which ramify in the adventitia. The significance of the afferent nerve fibres is uncertain, but some mediate pain impulses. 16 It is probable that the local anaesthetic, when injected into the venous lumen, rapidly diffused across the endothelium and the rather thin tunica media to reach the primary afferents in the adventitia, where nerve blockade is achieved. The observed efficacy of lignocaine in alleviating pain over a period of two hours is in accord with the known duration of local anaesthetic action of lignocaine on nerves.
Caution should be exercised whenever concentrated intravenous potassium infusions are used to correct hypokalaemia. Potential dangers include ECG change, dysrhythmia, transient hyperkalaemia and possible tissue necrosis from extravasation. A check serum potassium should always follow after treatment. Recently, a study by Robin et al.,17 showed that potassium infusions ranging from 20 to 40 mmol in 100 ml normal saline over one hour could be given to patients with pretreatment potassium levels < 3.5 mmolll without evidence of cardiovascular instability or compromise.
In conclusion, we found that the administration of potassium chloride solution is accompanied by a high incidence of pain. Pretreatment with a small, non-toxic, bolus dose of intravenous lignocaine significantly reduced this pain. The effect is not only immediate but persists over a useful period of time.
